Member Info for Lp160606

Lol perhaps pp, I truly hope beckman deliver and we get the opportunity to celebrate.

Do you disagree this opportunity is now heavily dependant on beckman success and if not, we will revisit the 70s?

Check my post history, never held an agenda. It’s the rampers you need to keep an eye on.. case and point the Friday Fomo rally posters.. wrong and wrong again.

Said for months approvals in August.. appear I was wrong.. and sp highs in October based off sentiment due to 2nd wave.. Got a shed load of stick when I was stating August for approvals as well.

David budd has absolutely decimated my enthusiasm for the share. Comms have been dreadful post placing. The software RNS release Conveniently released 3 mins after the laughable trading update.

Try looking at things objectively mate, Depict the poor trading update the timescales offered, then I’d advise to look real deep at Divoc, like actually do some research on them. Then have a little look at at the Indian approval process. Absolute cowboys.

Then come back and I’ll have a debate with you.

My average is 125 and I’ve listened to the same tosh on this board for months, £5 next week, £3 soon and it is all utter nonsense.

0 sales, 0 approvals.

Argue with the facts.

Beckman or bust. Fact.

I’ll sell when the opportunity presents itself, thanks Lloyd.

Beckman or bust. That’s the state of play.

I only saw the article today, hence the post.

Balance.

But hey ‘peels on bid’

Would suggest printing the entire article rather than a specific section to suit the narrative.

Abbott a multi billion company did 8% on a day due to this and although it may be more bluster from trump it plays into our key marketplace, and so naturally is relevant.

https://www.cnbc.com/amp/2020/08/27/trump-to-announce-750-million-deal-with-abbott-for-at-least-150-million-rapid-coronavirus-tests.html

But it is relevant.

We got to market late for the lab test and have suffered miserably - hence the show me our market share. As it will be the same for the poc testing.

All shouted about how good our current test that actually exists is, sales tell a different story.

Beneficial to lab owners, no better than any other test for government end users.

Can you point me to our current market share?

Happily review at your earliest convenience.

Slow & sluggish.

Will be irrelevant if they don’t get to market early.

Huge benefits to fastest mover as seen with Novacyt. GDR must not be 20th past the post.

Have very limited expectation regarding comms, expect Beckman to do the work for the SP as our one and only sales outlet.

Investor page was created exactly for that reason and to direct any further question to ‘our up to date schedule’ it’s the perfect fob off.

I know beckman will be a success as it will have minimal involvement from David Budd, given Cytiva and beckman sit under the same umbrella.

KD, which aspect of my statement do you actually disagree with?

That communications are poor from the company both in frequency and clarity or that lack of volume is a result of that?

Even when they do communicate it isn’t clear cut, that rushed up investor page is laughable. Slipping in commercial EU sales to protect the companies previous statements on June sales.

Although there is clearly a lack of volume, that is the not the root problem but a knock on effect of poor vocalised progress and mismanagement of communication from the leadership leading to a lack of interest hence the low volume.

Low volume is the cause of pitiful communications and progress in commercialising.

The lightning rod?

Disagreed with your poor baseless assumption that GDR were in the same boat as shareholders.

I’ll take it as you were unaware icmr had a portal for applicants as well.

GDR will be a success simply due to the Beckman opp.

Outside of that they’ve been specialists n failure when it comes to commercialising the offering.

I disagree.

Db actively reads this forum or at least walbrook do and feedback.

Over the course of the last few weeks we worked out approvals would land this week (wrongly or rightly)

All a bit convenient this ‘helpful’ page pops up on the week we expect news.

Pp,

Are you aware ICMR host a customer portal where all applicants can access round the clock to see the stage of their applications and request support on any further requirements? Includes a chat/support ticket function.

So, your belief that GDR are in the same boat as us is factually incorrect.

I’m sick of that clown David Budd.

Posted on LSE claiming we would all shortly benefit..
Shared a product comparison **** talking our competition and still sold nada. Other than 20 to the local corner store In Belarus.
Then when announcing beckman signed off with ‘good things come to those who wait’

The bloke is arrogant.

Cytiva orchestrated Beckman - Not David Budd.

And tbh this new page highlights everything wrong with his approach to shareholders.

Yes pp but that’s because much of your claims are nonsense and generally just ramping.

Although beneficial for new investors.

That is not the primary reason for that page. It will be as they keep getting asked the same questions by 100s of investors. It now allows them to fob off investors by pointing them to that landing page ‘for our up to date schedule’

The management of communications to investors here is absolutely abysmal. This page highlights it yet again.

Sales in Europe... well where and for how much?

We had all agreed this week would be where approvals come in after being pushed and pushed again... then this page conveniently goes live.

I concur Lloyd.

Great to see documented progress but we will be pointed to this page every time we raise a question on regulatory Progress from now on.

Also, why publish this page now in the week we are all expecting news, seems odd. Suggests news isn’t as close as we think.

Had to laugh scrolling through those comments and seeing Grim asking for an update... quality.

Can see there is a loose link to Doris Williams.
https://www.linkedin.com/in/dorisannwilliams/

Is interesting, perhaps we may get a surprise. Although that site is swamped with various methods and it is tricky to deduce anything other than an awareness of our test.

I do agree - automation certainly required in order to reach testing goals.

It is going to be a interesting few weeks.